NCT01023295

Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

OXiGENE OXC402-201: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Biological Effects of Intravenous Fosbretabulin in Asian Subjects With Polypoidal Choroidal Vasculopathy (PCV)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Mateon Therapeutics · Industry
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to examine effects of fosbretabulin tromethamine (fosbretabulin) on PCV as reflected by a change from baseline in the number of polypoid lesions on indocyanine green angiography (ICGA).

Conditions

• Polypoidal Choroidal Vasculopathy

Interventions

Type	Name	Description
DRUG	fosbretabulin	single dose, intravenous infusion
DRUG	Saline	single dose, intravenous infusion

Timeline

• Start date: 2009-07-01
• Primary completion: 2010-08-01
• Completion: 2010-08-01
• First posted: 2009-12-02
• Last updated: 2011-11-01

Locations

5 sites across 5 countries: United States, Hong Kong, Singapore, South Korea, Taiwan